The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 13, 2022

Filed:

Jun. 01, 2020
Applicant:

Nutrileads B.v., Wageningen, NL;

Inventors:

Maria Tzoumaki, Wageningen, NL;

Ruud Albers, Rockanje, NL;

Assignee:

NutriLeads B.V., Wageningen, NL;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/715 (2006.01); A61P 31/04 (2006.01); A61K 31/07 (2006.01); A23K 20/163 (2016.01); A23K 50/00 (2016.01); A23K 20/147 (2016.01); A23K 20/158 (2016.01); A23K 20/174 (2016.01); A23K 20/20 (2016.01); A23K 50/30 (2016.01); A23K 50/75 (2016.01); A23L 33/125 (2016.01); A23L 33/00 (2016.01); A23L 33/155 (2016.01);
U.S. Cl.
CPC ...
A61K 31/715 (2013.01); A23K 20/147 (2016.05); A23K 20/158 (2016.05); A23K 20/163 (2016.05); A23K 20/174 (2016.05); A23K 20/20 (2016.05); A23K 50/30 (2016.05); A23K 50/75 (2016.05); A23L 33/125 (2016.08); A23L 33/155 (2016.08); A23L 33/40 (2016.08); A61P 31/04 (2018.01); A23V 2002/00 (2013.01);
Abstract

The invention relates to a composition for use in the prevention or treatment of Salmonellosis in animals, said use comprising administering the composition to the animal, wherein the composition contains at least 0.01% by weight of dry matter of rhamnogalacturonan I (RG-I) polysaccharides having a molecular weight of more than 2 kDa and having a backbone consisting of galacturonic acid residues and rhamnose residues, said rhamnose residues being contained in alpha(1→4)-galacturonic-alpha(1→2)-rhamnose residues, wherein the molar ratio of galacturonic acid residues to rhamnose residues in the RG-I polysaccharides is within the range of 50:1 to 1:1. The use of RG-I polysaccharides in the treatment or prevention of Salmonellosis provides an alternative for the widespread use of antibiotics. Furthermore, these RG-I polysaccharides may be used to prevent or treat Salmonellosis caused bystrains with resistance to antibiotics.


Find Patent Forward Citations

Loading…